News
VRDN
17.85
-0.78%
-0.14
Viridian Therapeutics Enters Oversold Territory (VRDN)
NASDAQ · 10h ago
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
Barchart · 10h ago
Weekly Report: what happened at VRDN last week (1202-1206)?
Weekly Report · 4d ago
Viridian Therapeutics Price Target Maintained With a $44.00/Share by RBC Capital
Dow Jones · 12/05 16:15
RBC Capital Reiterates Outperform on Viridian Therapeutics, Maintains $44 Price Target
Benzinga · 12/05 16:05
VIRIDIAN THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/04 21:01
Weekly Report: what happened at VRDN last week (1125-1129)?
Weekly Report · 12/02 11:31
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
Benzinga · 11/25 13:58
Viridian Therapeutics Price Target Maintained With a $38.00/Share by Needham
Dow Jones · 11/25 12:06
Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target
Benzinga · 11/25 11:56
Buy Rating Reaffirmed for Viridian Therapeutics Ahead of Promising THRIVE-2 Trial Results
TipRanks · 11/25 11:45
Weekly Report: what happened at VRDN last week (1118-1122)?
Weekly Report · 11/25 11:22
TD Cowen Initiates Coverage On Viridian Therapeutics with Buy Rating
Benzinga · 11/25 11:09
Viridian Therapeutics: Buy Rating Due to Promising TED Therapy and Market Potential
TipRanks · 11/25 11:06
Viridian Therapeutics initiated with a Buy at TD Cowen
TipRanks · 11/25 11:00
Weekly Report: what happened at VRDN last week (1111-1115)?
Weekly Report · 11/18 11:19
Viridian Therapeutics (VRDN) Pioneering Breakthroughs in Thyroid Eye Disease
TipRanks · 11/18 10:29
Viridian Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/14 10:18
Viridian Therapeutics Price Target Raised to $34.00/Share From $27.00 by HC Wainwright & Co.
Dow Jones · 11/14 10:18
HC Wainwright & Co. Maintains Buy on Viridian Therapeutics, Raises Price Target to $34
Benzinga · 11/14 10:07
More
Webull provides a variety of real-time VRDN stock news. You can receive the latest news about Viridian Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About VRDN
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on advancing VRDN-001 as a potential intravenous therapy followed by VRDN-003 as a potential subcutaneous therapy for the treatment of TED. Its advanced program, VRDN-001, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED. In addition to its TED portfolio, the Company is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.